Skip to main content
SpringerLink
Log in

Oral versus Topical NSAIDs in Rheumatic Diseases

A Comparison

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed drugs worldwide and are responsible for approximately one-quarter of all adverse drug reaction reports. NSAIDs are widely prescribed for patients with rheumatic disease — a population at increased risk for serious gastrointestinal (GI) complications. Topical administration of NSAIDs offers the advantage of local, enhanced drug delivery to affected tissues with a reduced incidence of systemic adverse effects, such as peptic ulcer disease and GI haemorrhage.

NSAIDs administered topically penetrate slowly and in small quantities into the systemic circulation; bioavailability and maximal plasma NSAID concentration after topical application are generally less than 5 and 15%, respectively, compared with equivalent oral administration. Product formulation may have a dramatic impact, not only on absorption rates but also on penetration depth. Compared with oral administration, topical application leads to relatively high NSAID concentrations in the dermis. Concentrations achieved in the muscle tissue below the site of application are variable, but are at least equivalent to that obtained with oral administration. NSAIDs applied topically do reach the synovial fluid, but the extent and mechanism (topical penetration versus distribution via the systemic circulation) remain to be determined. In addition, marked interindividual variability was noted in all studies; percutaneous absorption may be strongly influenced by individual skin properties.

In general, interpretation of clinical studies measuring efficacy of topical NSAIDs in rheumatic disease states is difficult because of a remarkably high placebo response rate, use of rescue paracetamol (acetaminophen), and significant variability in percutaneous absorption and response rates between patients. Overall efficacy rates attributable to topical NSAIDs in patients with rheumatic disorders ranged from 18 to 92% of treated patients. Topically applied NSAIDs have a superior safety profile to oral formulations. Adverse effects secondary to topical NSAID application occur in approximately 10 to 15% of patients and are primarily cutaneous in nature (rash and pruritus at site of application). GI adverse drug reactions are rare with topically applied NSAIDs, compared with a 15% incidence reported for oral NSAIDs. Available clinical studies suggest, but do not document, equivalent efficacy of topical over oral NSAIDs in rheumatic diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Grahame R. The NSAID patch [editorial]. Eur J Rheumatol Inflamm 1994; 14(4): 1–2

    PubMed  CAS  Google Scholar 

  2. Grahame R. Transdermal nonsteroidal anti-inflammatory agents. Br J Clin Pract 1995 Jan-Feb; 49(1): 33–5

    PubMed  CAS  Google Scholar 

  3. Vaile JH, Davis P. Topical NSAIDs for musculoskeletal conditions: a review of the literature. Drugs 1998 Nov; 56(5): 783–99

    Article  PubMed  CAS  Google Scholar 

  4. Heyneman CA. Topical nonsteroidal anti-inflammatory drugs for acute soft tissue injuries. Ann Pharmacother 1995 Jul–Aug; 29(7-8): 780–2

    PubMed  CAS  Google Scholar 

  5. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996 May; 39(5): 713–22

    Article  Google Scholar 

  6. Schumacher HR. Classification of the rheumatic diseases. In: Schumacher Jr HR, editor. Primer on the rheumatic diseases. 10th ed. Atlanta (GA): Arthritis Foundation, 1993: 2–6

    Google Scholar 

  7. Paulus HE, Bulpitt KJ. Nonsteroidal anti-inflammatory agents and corticosteroids. In: Schumacher Jr HR, editor. Primer on the rheumatic diseases. 10th ed. Atlanta (GA): Arthritis Foundation, 1993: 298–303

    Google Scholar 

  8. Boh LE. Osteoarthritis. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiological approach. 4th ed. Narwalk (CT): Appleton & Lange, 1999: 1441–59

    Google Scholar 

  9. Bagge E, Brooks P. Osteoarthritis in older patients: optimum treatment. Drugs Aging 1995 Sep; 7(3): 176–83

    Article  PubMed  CAS  Google Scholar 

  10. Biundo JJ. Regional rheumatic pain syndromes. In: Schumacher Jr HR, editor. Primer on the rheumatic diseases. 10th ed. Atlanta (GA): Arthritis Foundation, 1993: 277–87

    Google Scholar 

  11. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. BMJ 1998 Aug 22; 317(7157): 526–30

    Article  PubMed  CAS  Google Scholar 

  12. Schnitzer TJ. Osteoarthritis treatment update: minimizing pain while limiting patient risk. Postgrad Med 1993 Jan; 93(1): 89–92, 95

    PubMed  CAS  Google Scholar 

  13. Hochberg MC, Alrman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis: part II. Osteoarthritis of the knee. Arthritis Rheum 1995; 38: 1541–6

    CAS  Google Scholar 

  14. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971 Jun 23; 231(25): 232–5

    PubMed  CAS  Google Scholar 

  15. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs: differences and similarities. N Engl J Med 1991 Jun 13; 324(24): 1716–25

    Article  PubMed  CAS  Google Scholar 

  16. Gierse JK, Koboldt CM, Walker MC, et al. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 1999 May 1; 339 Pt 3: 607–14

    Article  Google Scholar 

  17. Squire I, Lees K. Topical drug delivery. Practitioner 1992 Feb; 236: 203–6

    PubMed  CAS  Google Scholar 

  18. Yano T, Nakagawa A, Tsuji M, et al. Skin permeability of various non-steroidal anti-inflammatory drugs in man. Life Sci 1986 Sep 22; 39(12): 1043–50

    Article  PubMed  CAS  Google Scholar 

  19. Brown MB, Marriott C, Martin GP. The effect of hyaluronan on the in vitro deposition of diclofenac within the skin. Int J Tissue React 1995; 17(4): 133–40

    PubMed  CAS  Google Scholar 

  20. Rao PR, Diwan PV. Formulation and in vitro evaluation of polymeric films of diltiazem hydrochloride and indomethacin for transdermal administration. Drug Dev Ind Pharm 1998 Apr; 24(4): 327–36

    Article  PubMed  CAS  Google Scholar 

  21. Tomida H, Shinohara M, Kuwada N, et al. In vitro release characteristics of diclofenac and hydrocortisone from Pluronic F-127 gels. Acta Pharm Suec 1987; 24(5): 263–72

    PubMed  CAS  Google Scholar 

  22. Priborsky J, Takayama K, Obata Y. Influence of limonene and laurocapram on percutaneous absorption of nonsteroidal anti-inflammatory drugs. Arzneimittelforschung 1992 Feb; 42(2): 116–9

    PubMed  CAS  Google Scholar 

  23. Singh SK, Durrani MJ, Reddy IK. Effect of permeation enhancers on the release of ketoprofen through transdermal drug delivery systems. Pharmazie 1996 Oct; 51(10): 741–4

    PubMed  CAS  Google Scholar 

  24. Friedman DI, Schwarz JS, Weisspapir M. Submicron emulsion vehicle for enhanced transdermal delivery of steroidal and nonsteroidal anti-inflammatory drugs. J Pharm Sci 1995 Mar; 84(3): 324–9

    Article  PubMed  CAS  Google Scholar 

  25. Singh P, Anlike M, Smith GA, et al. Transdermal iontophoresis and solute penetration across excised human skin. J Pharm Sci 1995 Nov; 84(11): 1342–6

    Article  PubMed  CAS  Google Scholar 

  26. Akhter SA, Barry BW. Absorption through human skin of ibuprofen and flurbiprofen: effect of dose variation, deposited drug films, occlusion and the penetration enhancer N-methyl-2-pyrrolidone. J Pharm Pharmacol 1985 Jan; 37(1): 27–37

    Article  PubMed  CAS  Google Scholar 

  27. McNeill SC, Potts RO, Francoeur ML. Local enhanced topical delivery (LETD) of drugs: does it truly exist? Pharm Res 1992 Nov; 9(11): 1422–7

    Article  PubMed  CAS  Google Scholar 

  28. Mikulak SA, Vangsness CT, Nimni ME. Transdermal delivery and accumulation of indomethacin in subcutaneous tissues in rats. J Pharm Pharmacol 1998 Feb; 50(2): 153–8

    Article  PubMed  CAS  Google Scholar 

  29. Singh P, Roberts MS. Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application. J Pharmacol Exp Ther 1994 Jan; 268(1): 144–51

    PubMed  CAS  Google Scholar 

  30. Treffel P, Bagard B. Ibuprofen epidermal levels after topical application in vitro: effect of formulation, application time, dose variation and occlusion. Br J Dermatol 1993 Sep; 129(3): 286–91

    Article  PubMed  CAS  Google Scholar 

  31. Cordero JA, Alarcon L, Escribano E, et al. A comparative study of the transdermal penetration of a series of nonsteroidal anti-inflammatory drugs. J Pharm Sci 1997 Apr; 86(4): 503–8

    Article  PubMed  CAS  Google Scholar 

  32. Roy SD, Manoukian E. Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. J Pharm Sci 1995 Oct; 84(10): 1190–6

    Article  PubMed  CAS  Google Scholar 

  33. Seth BL. Comparative pharmacokinetics and bioavailability study of percutaneous absorption of diclofenac from two topical formulations containing drug as a solution gel or as an emulsion gel. Arzneimittelforschung 1992 Feb; 42(2): 120–2

    PubMed  CAS  Google Scholar 

  34. Seth PL. Percutaneous absorption of ibuprofen from different formulations: comparative study with gel, hydrophilic ointment and emulsion cream. Arzneimittelforschung 1993 Aug; 43(8): 919–21

    PubMed  CAS  Google Scholar 

  35. Roy SD, Manoukian E, Combs D. Absorption of transdermally delivered ketorolac acid in humans. J Pharm Sci 1995 Jan; 84(1): 49–52

    Article  PubMed  CAS  Google Scholar 

  36. Gevi M, Merlo M. Ketoprofen lysine by topical route in sports traumatology. Curr Ther Res 1983 Nov; 34(5): 844–50

    Google Scholar 

  37. Kanazawa M, Ito H. The pharmacokinetics of 0.5% piroxicam gel in humans. Eur J Rheumatol Inflamm 1997; 8(1): 117

    Google Scholar 

  38. Muller M, Rastelli C, Ferri P, et al. Transdermal penetration of diclofenac after multiple epicutaneous administration. J Rheumatol 1998 Sep; 25(9): 1833–6

    PubMed  CAS  Google Scholar 

  39. Assandri A, Canali S, Giachetti C. Local tolerability and pharmacokinetic profile of a new transdermal delivery system, diclofenac hydroxyethylpyrrolidine plaster. Drugs Exp Clin Res 1993; 19(3): 89–95

    PubMed  CAS  Google Scholar 

  40. Shah AK, Wei G, Lanman RC, et al. Percutaneous absorption of ketoprofen from different anatomical sites in man. Pharm Res 1996 Jan; 13(1): 168–72

    Article  PubMed  CAS  Google Scholar 

  41. Sioufi A, Pommier F, Boschet F, et al. Percutaneous absorption of diclofenac in healthy volunteers after single and repeated topical application of diclofenac Emulgel. Biopharm Drug Dispos 1994 Aug; 15(6): 441–9

    Article  PubMed  CAS  Google Scholar 

  42. Taburet AM, Singlas E, Glass RC, et al. Pharmacokinetic comparison of oral and local action transcutaneous flurbiprofen in healthy volunteers. J Clin Phann Ther 1995 Apr; 20(2): 101–7

    Article  CAS  Google Scholar 

  43. Flouvat B, Roux A, Delhotal-Landes B. Pharmacokinetics of ketoprofen in man after repeated percutaneous administration. Arzneimittelforschung 1989 Jul; 39(7): 812–5

    PubMed  CAS  Google Scholar 

  44. Tegeder I, Muth-Selbach U, Lotsch J, et al. Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. Clin Pharmacol Ther 1999 Apr; 65(4): 357–68

    Article  PubMed  CAS  Google Scholar 

  45. Dominkus M, Nicolakis M, Kotz R, et al. Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Arzneimittelforschung 1996 Dec; 46(12): 1138–43

    PubMed  CAS  Google Scholar 

  46. McNeil Consumer Products Co. Motrin (ibuprofen) [package insert-revised]. Fort Washington (PA): McNeil Consumer Products Co., Dec 1994

    Google Scholar 

  47. Rolf C, Engstrom B, Beauchard C, et al. Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology (Oxford) 1999 Jun; 38(6): 564–7

    Article  CAS  Google Scholar 

  48. Cushman DW, Cheung HS. Effect of substrate concentration on inhibition of prostaglandin synthetase of bull seminal vesicles by anti-inflammatory drugs and fenamic acid analogs. Biochim Biophys Acta 1976 Mar 26; 424(3): 449–59

    Article  PubMed  CAS  Google Scholar 

  49. Gallacchi G, Marcolongo R. Pharmacokinetics of diclofenac hydroxyethylpyrrolidine (DHEP) plasters in patients with monolateral knee joint effusion. Drugs Exp Clin Res 1993; 19(3): 95–7

    PubMed  CAS  Google Scholar 

  50. Day RO, McLachlan AT, Graham GG, et al. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 1999 Mar; 36(3): 191–210

    Article  PubMed  CAS  Google Scholar 

  51. Mattara L, Trotta F, Biasi D, et al. Evaluation of the efficacy and tolerability of a new locally acting preparation of flurbiprofen in scapulohumeral periarthritis. Eur J Rheumatol Inflamm 1994; 14(4): 15–20

    PubMed  CAS  Google Scholar 

  52. Poul J, West J, Buchanan N, et al. Local action transcutaneous flurbiprofen in the treatment of soft tissue rheumatism. Br J Rheumatol 1993 Nov; 32(11): 1000–3

    Article  PubMed  CAS  Google Scholar 

  53. Saggini R, Zoppi M, Vecchiet F, et al. Comparison of electromotive drug administration with ketorolac or with placebo in patients with pain from rheumatic disease: a double-masked study. Clin Ther 1996 Nov-Dec; 18(6): 1169–74

    Article  PubMed  CAS  Google Scholar 

  54. Shackel NA, Day RO, Kellett B, et al. Copper-salicylate gel for pain relief in osteoarthritis: a randomised controlled trial. Med J Aust 1997 Aug 4; 167(3): 134–6

    PubMed  CAS  Google Scholar 

  55. Dreiser RL, Tisne-Camus M. DFfEP plasters as a topical treatment of knee osteoarthritis: a double-blind placebo-controlled study. Drugs Exp Clin Res 1993; 19(3): 117–23

    PubMed  CAS  Google Scholar 

  56. Galeazzi M, Marcolongo R. A placebo-controlled study of the efficacy and tolerability of a nonsteroidal anti-inflammatory drug, DHEP plaster, in inflammatory peri- and extra-articular rheumatological diseases. Drugs Exp Clin Res 1993; 19(3): 107–15

    PubMed  CAS  Google Scholar 

  57. Roth SH. A controlled clinical investigation of 3% diclofenac/2.5% sodium hyaluronate topical gel in the treatment of uncontrolled pain in chronic oral NS AID users with osteoarthritis. Int J Tissue React 1995; 17(4): 129–32

    PubMed  CAS  Google Scholar 

  58. Ginsberg F, Famaey JP Double-blind, randomized crossover study of the percutaneous efficacy and tolerability of a topical indomethacin spray versus placebo in the treatment of tendinitis. J Int Med Res 1991 Mar-Apr; 19(2): 131–6

    PubMed  CAS  Google Scholar 

  59. Grace D, Rogers J, Skeith K, et al. Topical diclofenac versus placebo: a double blind randomized clinical trial in patients with osteoarthritis of the knee. J Rheumatol 1999; 26: 2659–63

    PubMed  CAS  Google Scholar 

  60. Waikakukl S, Danputipong P, Soparat K. Topical analgesics, indomethacin plaster and diclofenac emulgel for low back pain: a parallel study. J Med Assoc Thai 1996 Aug; 79(8): 486–90

    Google Scholar 

  61. Ritchie LD. A clinical evaluation of flurbiprofen LAT and piroxicam gel: a multicentre study in general practice. Clin Rheumatol 1996 May; 15(3): 243–7

    Article  PubMed  CAS  Google Scholar 

  62. Rosenthal M, Bahous I. A controlled clinical study on the new topical dosage form of DHEP plasters in patients suffering from localized inflammatory diseases. Drugs Exp Clin Res 1993; 19(3): 99–105

    PubMed  CAS  Google Scholar 

  63. Giacovazzo M. Clinical evaluation of a new NSAID applied topically (BPAA gel) vs. diclofenac emulgel in elderly osteoarthritic patients. Drugs Exp Clin Res 1992; 18(5): 201–3

    CAS  Google Scholar 

  64. Hosie G, Bird H. The topical NSAID felbinac versus oral NSAIDS: a critical review. Eur J Rheumatol Inflamm 1994; 14(4): 21–8

    PubMed  CAS  Google Scholar 

  65. Tsuyama N, Kurokawa T, Hihei T, et al. Clinical evaluation of L-141 topical agent on osteoarthrosis deformans of the knees. Clin Med 1985; 1:697–729

    Google Scholar 

  66. Martens M. Efficacy and tolerability of a topical NSAID patch (local action transcutaneous flurbiprofen) and oral diclofenac in the treatment of soft-tissue rheumatism. Clin Rheumatol 1997 Jan; 16(1): 25–31

    Article  PubMed  CAS  Google Scholar 

  67. Sandelin J, Harilainen A, Crone H, et al. Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee: a double blind study comparing eltenac with oral diclofenac and placebo gel. Scand J Rheumatol 1997; 26(4): 287–92

    Article  PubMed  CAS  Google Scholar 

  68. Dickson DJ. A double-blind evaluation of topical piroxicam gel with oral ibuprofen in osteoarthritis of the knee. Curr Ther Res 1991 Feb; 49(2): 199–207

    Google Scholar 

  69. Browning RC, Johson K. Reducing the dose of oral NSAIDs by use of Feldene Gel: an open study in elderly patients with osteoarthritis. Adv Ther 1994 Jul–Aug; 11(4): 198–207

    PubMed  CAS  Google Scholar 

  70. Evans JM, MacDonald TM. Tolerability of topical NSAIDs in the elderly: do they really convey a safety advantage? Drugs Aging 1996 Aug; 9(2): 101–8

    Article  PubMed  CAS  Google Scholar 

  71. Wynne HA, Rawlins MD. Are systemic levels of nonsteroidal anti inflammatory drugs relevant to acute upper gastrointestinal haemorrhage? Eur J Clin Pharmacol 1993; 44(4): 309–13

    Article  PubMed  CAS  Google Scholar 

  72. Evans JMM, McGregor E, McMahon AD, et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. Q J Med 1995 Aug; 88(8): 551–7

    CAS  Google Scholar 

  73. Carson JL, Strom BL, Soper KA, et al. The association of non-steroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med 1987 Jan; 147: 85–8

    Article  PubMed  CAS  Google Scholar 

  74. Figueras A, Capella D, Castel JM, et al. Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs: a report from the Spanish System of Pharmacovigilance, including an early analysis of topical and enteric-coated formulations. Eur J Clin Pharmacol 1994; 47(4): 297–303

    Article  PubMed  CAS  Google Scholar 

  75. Evans JMM, McMahon AD, McGilchrist MM, et al. Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ 1995 Jul 1; 311(6996): 22–6

    Article  PubMed  CAS  Google Scholar 

  76. Ophaswongse S, Maibach H. Topical nonsteroidal antiinflammatory drugs: allergic and photoallergic contact dermatitis and phototoxicity. Contact Dermatitis 1993 Aug; 29(2): 57–64

    Article  PubMed  CAS  Google Scholar 

  77. Singh G, Ramey DR, Morfeld D, et al. Comparative toxicity of non-steroidal anti-inflammatory agents. Pharmacol Ther 1994 Apr–May; 62(1-2): 175–91

    Article  PubMed  CAS  Google Scholar 

  78. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996 Jul 22; 156(14): 1530–6

    Article  PubMed  CAS  Google Scholar 

  79. Vestal RE. Geriatric clinical pharmacology: an overview. In: Vestal RE, editor. Drug therapy in the elderly. Sydney: ADIS Health Science Press, 1984: 12–28

    Google Scholar 

  80. Joint Working Group of the British Society for Rheumatology and the Research Unit of the Royal College of Physicians: guidelines for the diagnosis, investigation and management of osteoarthritis of the hip and knee. J R Coll Physicians Lond 1993; 27: 391–6

    Google Scholar 

  81. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: ameta-analysis. Ann InternMed 1991 Nov 15; 115(10): 787–96

    CAS  Google Scholar 

  82. Topical NSAIDs: a gimmick or a godsend [editorial]? Lancet 1989 Sep 30; 2(8666): 779–80

    PubMed  Google Scholar 

  83. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988 Feb 22; 84(2A): 20–4

    Article  PubMed  CAS  Google Scholar 

  84. Liu K, Chia Y-Y, Lo Y, et al. Effect of preoperative transdermal ketoprofen on post-hysterectomy pain. Chung Hua I Hsueh Tsa Chih (Taipei) 1997 Dec; 60(6): 290–5

    CAS  Google Scholar 

  85. Reinhart DJ, Goldberb MI, Roth JV, et al. Transdermal fentanyl system plus im ketorolac for the treatment of postoperative pain. Can J Anaesth 1997 Apr; 44(4): 377–84

    Article  PubMed  CAS  Google Scholar 

  86. De Benedittis G, Lorenzetti A. Topical aspirin/diethyl ether mixture versus indomethacin and diclofenac/diethyl ether mixtures for acute herpetic neuralgia and postherpetic neuralgia: a double-blind crossover placebo-controlled study. Pain 1996 Apr; 65(1): 45–51

    Article  Google Scholar 

  87. Lawrence HP, Paquette DW, Smith PC, et al. Pharmacokinetic and safety evaluations of ketoprofen gels in subjects with adult periodontitis. J Dent Res 1998 Nov; 77(11): 1904–12

    Article  PubMed  CAS  Google Scholar 

  88. Saxen MA, Ambrosius WR, Rehemtula al-KF, et al. Sustained relief of oral aphthous ulcer pain from topical diclofenac in hyaluronan: a randomized, double-blind clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Oct; 84(4): 356–61

    Article  PubMed  CAS  Google Scholar 

  89. Rivers JK. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997 Oct; 133(10): 1239–42

    Article  PubMed  CAS  Google Scholar 

  90. Hiramatsu Y, Akita S, Salamin PA, et al. Assessment of topical non-steroidal anti-inflammatory drugs in animal models. Arzneimittelforschung 1990 Oct; 40(10): 1117–24

    PubMed  CAS  Google Scholar 

  91. Moore RA, Tramer MR, Carroll D. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998 Jan 31; 316(7128): 333–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice and Administrative Sciences, Idaho State University College of Pharmacy, Pocatello, Idaho, USA

    Catherine A. Heyneman (Assistant Professor of Pharmacy Practice) & Cara Lawless-Liday

  2. Department of Pharmacy Practice, Drake University College of Pharmacy, Des Moines, Iowa, USA

    Geoffrey C. Wall

Authors
  1. Catherine A. Heyneman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cara Lawless-Liday
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Geoffrey C. Wall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherine A. Heyneman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heyneman, C.A., Lawless-Liday, C. & Wall, G.C. Oral versus Topical NSAIDs in Rheumatic Diseases. Drugs 60, 555–574 (2000). https://doi.org/10.2165/00003495-200060030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200060030-00004

Keywords

Search

Navigation